Ted Schwartz, a cancer survivor, gifted $15M to City of Hope that will be used entirely to further accelerate immunotherapy research and treatment innovations, such as the CAR T-cell therapy that saved his life.
The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. announced a worldwide exclusive license agreement and clinical trial agreement to develop and advance AmMax’s AMB-066 monoclonal antibody therapy as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease as well as those with MRD in other solid tumors.
